{"title":"New Perspectives in the Treatment of Inflammatory Myofibroblastic Tumor with ALK Translocation: Case Report.","authors":"Johana Benedetti Pedroza, Irene Carrasco García, Gala Martínez Bernal, Isabel Miras Rodriguez","doi":"10.1159/000539739","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory myofibroblastic tumor (IMT) is a rare entity, classified within soft tissue sarcomas. It is an intermediate malignancy tumor, which seldom presents as metastatic disease. The treatment of choice is surgery, except in cases where surgery is not possible due to localization or if it presents with metastatic disease. Approximately 50% of IMTs will exhibit ALK translocation, providing a therapeutic target for these patients.</p><p><strong>Case presentation: </strong>A case is presented of a patient with metastatic IMT in complete response to treatment with alectinib, maintained for over 4 years.</p><p><strong>Conclusion: </strong>This case showed a long time complete response in patient with IMT treated with alectinib.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324221/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Inflammatory myofibroblastic tumor (IMT) is a rare entity, classified within soft tissue sarcomas. It is an intermediate malignancy tumor, which seldom presents as metastatic disease. The treatment of choice is surgery, except in cases where surgery is not possible due to localization or if it presents with metastatic disease. Approximately 50% of IMTs will exhibit ALK translocation, providing a therapeutic target for these patients.
Case presentation: A case is presented of a patient with metastatic IMT in complete response to treatment with alectinib, maintained for over 4 years.
Conclusion: This case showed a long time complete response in patient with IMT treated with alectinib.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
